Hikma Pharmaceutical | HIK - Cash And Equivalent


Hikma Pharmaceutical reported $236M in Cash and Equivalent for its fiscal semester ending in June of 2025.





Cash And Equivalent Change Date
Almirall EUR 337.77M 14.83M Dec/2025
argenx SE USD 4.3B 808.71M Mar/2026
AstraZeneca USD 7.56B 1.85B Mar/2026
Autolus Therapeutics Ltd USD 130.92M 26.79M Mar/2026
Bayer EUR 6.67B 774M Dec/2025
Fresenius EUR 1.31B 81M Dec/2025
Genmab DKK 1.72B 46M Dec/2025
GlaxoSmithKline GBP 3.44B 292M Mar/2026
GRIFOLS EUR 801M 242.31M Dec/2025
Hikma Pharmaceutical USD 236M 48M Jun/2025
Lakefront Biotherapeutics EUR 66.8M 21.06M Mar/2026
Lonza CHF 719M 188M Dec/2025
Merck EUR 2.33B 77M Dec/2025
Orion EUR 199.3M 38.4M Mar/2026
Recordati EUR 428.82M 42.64M Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
UCB EUR 1.57B 1.14B Dec/2024